The study on Transplant Diagnostics Market involved four major activities in estimating the current size of the transplant diagnostics market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Download PDF Brochure: @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2531061
The transplant diagnostics market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.
Based on product, the reagents & consumables segment held the largest share of the market in 2019.
On the basis of product, the transplant diagnostics market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest share of the global transplant diagnostics market in 2019. Factors such as the increasing patient emphasis on effective and early patient profiling during organ transplantation and the growing adoption of transplant diagnostic techniques in related research studies are driving the growth of this segment.
Based on technology, the molecular assays segment is expected to witness the highest growth during the forecast period.
On the basis of technology, the transplant diagnostics market is segmented into molecular assay and non-molecular assay technology. The molecular assay technology segment is expected to register the highest CAGR during the forecast period. Factors such as its varied applications in patient profiling, rising public-private investments to support product development, and increasing clinical evidence of its efficacy are driving the growth of this segment.
Based on the transplant type, the solid organ transplantation segment accounted for the largest share of this market in 2019.
On the basis of transplant type, the transplant diagnostics market is categorized into solid organ, stem cell, and soft tissue transplantation. Solid organ transplantation accounted for the largest share of the transplant diagnostics market in 2019. Supportive government regulations to increase organ donations across major healthcare markets, the rising number of chronic diseases/disorders leading to transplantation, and ongoing technological advancements in the field of transplant diagnostics are the key factors supporting the growth of the market for solid organ transplantation.
North America accounted for the largest share of the transplant diagnostics market in 2019
North America accounted for the largest share of the transplant diagnostics market in 2019, followed by Europe. This can primarily be attributed to the continuous commercialization of innovative transplant diagnostic products coupled with ongoing advancements in the field of genomics and proteomics, recent discovery genetic biomarkers & their clinical role in immunoassay testing, and the increasing prevalence of chronic and communicable diseases.
Some of the prominent players in the transplant diagnostics market are Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Others are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), and GenDx (Netherlands).
Bio-Rad Laboratories, Inc. is the leading player in the global transplant diagnostics market. The company has a broad range of automated instruments for antibody screening and analysis, semi-automated systems for serological assays, standalone systems & reagents for molecular and non-molecular assay procedures, including transplant diagnostic products. The company has a keen focus on leveraging its core technologies by introducing product line extensions as well as new product offerings. GE Healthcare also seeks strategic partners to develop products. The company tries to evaluate new, emerging, and complementary technologies to identify new product opportunities.